- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr David L. Porter Explains Variations in CAR-T Cell Trial Criteria
The criteria to enroll cancer patients in a clinical trial of CAR-T cells vary according to their disease, past therapy, and how far along they are in different treatments, said David L. Porter, MD, of the University of Pennsylvania Health System.
The criteria to enroll cancer patients in a clinical trial of CAR-T cells vary according to their disease, past therapy, and how far along they are in different treatments, said David L. Porter, MD, of the University of Pennsylvania Health System.
Transcript (slightly modified)
What are the criteria to enroll patients in a CAR-T cells clinical trial?
So there are a number of different CAR-T cells trials, and the criteria vary according to the patient’s disease, the actual trial that is ongoing. Right now, most CAR-T cells trials are really in the early- to mid-stage of development, and it is primarily for patients who have advanced disease who have largely been through many other different therapies and they’re not working. So it’s for patients who are running out of treatment options.
That said, we’ve been doing this now for, gosh, over 6 years, and have learned a lot more about where it’s effective, when it works, when it might not work, and in fact what a lot of the side effects are and how to manage them. Now that we know that, and we understand the side effects and the safety issues, some of the trials are starting to treat patients earlier in the course of their disease. And the criteria there are obviously very different, they’re not just for somebody who’s failed every other treatment.
So it really will vary according to somebody’s past therapy, it will vary according to their disease, and how far along they are in the different treatments.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More
